$11.68
11.66% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Omeros Corporation Stock price

$11.68
-0.23 1.93% 1M
+7.73 195.70% 6M
+8.41 257.19% YTD
+8.42 258.28% 1Y
+4.40 60.44% 3Y
-3.32 22.13% 5Y
-12.23 51.15% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+1.22 11.66%
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Key metrics

Market capitalization $676.85m
Enterprise Value $987.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-173.36m
Free Cash Flow (TTM) Free Cash Flow $-154.91m
Cash position $123.16m
EPS (TTM) EPS $-2.30
P/E forward negative
Short interest 16.10%
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

Buy
50%
Hold
50%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.85 0.85
0% 0%
-
-0.85 -0.85
0% 0%
-
- Selling and Administrative Expenses 47 47
7% 7%
-
- Research and Development Expense 124 124
11% 11%
-
-173 -173
5% 5%
-
- Depreciation and Amortization 0.85 0.85
0% 0%
-
EBIT (Operating Income) EBIT -173 -173
5% 5%
-
Net Profit -135 -135
773% 773%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Neutral
Business Wire
10 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-t...
Neutral
Business Wire
27 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts ar...
Neutral
Business Wire
about one month ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In l...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 198
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today